Understanding the key to targeting the IGF axis in cancer: a biomarker assessment
Type 1 insulin like growth factor receptor (IGF-1R) targeted therapies showed compelling pre-clinical evidence; however, to date, this failed to translate to patient benefit in Phase 2/3 trails in unselected patients. This was further complicated by the toxicity, including hyperglycemia, which larg...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00142/full |